MAPT and Alzheimer disease: CSF values of the major constituents of AD pathology, tau and β-amyloid, (Aβ1−42) have been widely studied using immune-based analytical platforms in AD and amnestic mild cognitive impairment (MCI) patients, with lower Aβ1−42 values and higher levels of total- and phosphorylated-tau (t-tau, p-tau) compared with controls across multiple large studies (Shaw et al., 2009, 2011; De Meyer et al., 2010; Trojanowski et al., 2010; Weiner et al., 2010).